Ind-Swift Laboratories Ltd Quarterly Results
Q3 FY25-26 Results Summary
Revenue
The revenue stands at ₹150.85 crore, reflecting a quarter-on-quarter *(QoQ) decrease of 1.17 per cent from ₹152.64 crore. This corresponds to a year-on-year *(YoY) growth of 17.12 per cent.
Operating Profit
Operating Profit stands at ₹-1.68 crore, reflecting a quarter-on-quarter *(QoQ) decrease of 214.29 per cent from ₹1.47 crore. This corresponds to a year-on-year *(YoY) growth of 77.20 per cent.
PBDT
PBDT stands at ₹25.25 crore, reflecting a quarter-on-quarter *(QoQ) increase of 46.21 per cent from ₹17.27 crore. This corresponds to a year-on-year *(YoY) growth of 3,422.37 per cent.
Profit Before Tax
Profit Before Tax stands at ₹16.41 crore, reflecting a quarter-on-quarter *(QoQ) increase of 59.48 per cent from ₹10.29 crore. This corresponds to a year-on-year *(YoY) growth of 349.77 per cent.
Net Profit
Net Profit stands at ₹9.54 crore, reflecting a quarter-on-quarter *(QoQ) increase of 19.40 per cent from ₹7.99 crore. This represents a 273.77 per cent year-on-year *(YoY) growth for the same year.
- YoY compares a quarter to the same period last year, and QoQ compares it to the previous quarter.
Market News
Ind-Swift Laboratories Ltd Earnings
- YOY
- QOQ
Ind-Swift Laboratories Ltd Earning Charts
Revenue from Operations
in ₹ cr
EBITDA
in ₹ cr
Profit before Tax
in ₹ cr
Net Profit
in ₹ cr
Ind-Swift Laboratories Ltd Research Reports
| Action | Target Price (₹) | Broker | Date | Reports |
|---|---|---|---|---|
| Data Not Found | ||||
Ind-Swift Laboratories Ltd Financial Reports
Ind-Swift Laboratories Ltd Stock Prices Compare with Peers
| Company | 1 Day | 1 Week | 1 month | 3 month | 6 month | 1 Year |
|---|---|---|---|---|---|---|
| Ind-Swift Labs. | 1.59% | -1.25% | -0.11% | -7.53% | 39.81% | 75.79% |
| Jagsonpal Pharma | 2.43% | 5.31% | 3.48% | 24.88% | 4.02% | -8.52% |
| Fredun Pharma | -0.53% | -2.19% | 16.29% | 45.98% | 25.43% | 207.08% |
| Shukra Pharma. | -1.18% | -7.95% | -11.02% | -32.86% | -26.28% | 112.84% |
| Bajaj Healthcare | 1.22% | 2.44% | -8.05% | -7.07% | -28.34% | -45.40% |
| Wanbury | 0.65% | 5.54% | 9.47% | 7.06% | 12.78% | 0.85% |
| Themis Medicare | 6.85% | 9.12% | 9.59% | 23.81% | 0.52% | -25.59% |
Company Info
Company Information
Chairman / Executive Director / M D / Promoter : N R Munjal
ED / Joint MD / Promoter : Himanshu Jain
Executive Director : Rishav Mehta
Executive Director : Sahil Munjal
Independent Non Executive Women Director : Neerja Chathley
Independent Non Exe. Director : Rajinder Kumar Gupta
Independent Non Exe. Director : SUBODH GUPTA
Independent Non Exe. Director : Prabhat Khurana
VP / Company Secretary / Compliance Officer : Pradeep Verma